MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.39 2.96

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.38

Max

1.3900000000000001

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+43.88% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-22M 152M
Eelmine avamishind	-1.57
Eelmine sulgemishind	1.39

Uudiste sentiment

By Acuity

34%

66%

78 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. apr 2026, 23:48 UTC

Uudisväärsed sündmused

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19. apr 2026, 23:36 UTC

Uudisväärsed sündmused

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19. apr 2026, 22:47 UTC

Uudisväärsed sündmused

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19. apr 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19. apr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19. apr 2026, 23:38 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19. apr 2026, 23:12 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19. apr 2026, 23:10 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19. apr 2026, 23:09 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19. apr 2026, 23:08 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19. apr 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19. apr 2026, 20:03 UTC

Uudisväärsed sündmused

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18. apr 2026, 01:00 UTC

Uudisväärsed sündmused

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

43.88% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 43.88%

Kõrge 2 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

78 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.